Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial

Syed Wasif Gillani1,2,3*, Syed Azhar Syed Sulaiman4, Mohi Iqbal Mohammad Abdul1,5 and Mirza R. Baig6

Abstract

Background: We aimed to investigate the efficacy of ascorbic acid and acetylsalicylic acid among type II diabetes mellitus patients using metformin (only) for diabetes management therapy.

Method: A 12-month single blinded multicenter randomized control trial was designed to investigate the measured variables [Glycated Hemoglobin (HbA1c), Renal function, Albumin Creatinine Ratio (ACR) etc.]. The trial was randomized into 2 experimental parallel arms (ascorbic acid vs acetylsalicylic acid) were blinded with study supplements in combination with metformin and findings were compared to control arm with metformin alone and blinded with placebo. Withdrawal criteria was defined to maintain the equity and balance in the participants in the whole trial.

Finding: Patients with metformin and ascorbic acid (parallel arm I) was twice more likely to reduce HbA1c than metformin alone (control arm) in a year (OR 2.31 (95% CI 1.87–4.42) \( p < 0.001 \)). Also Parallel arm I was ten times more likely to reduced risk factors contributing to long-term diabetes complications than participants of arm II in a year (OR 10.38 (95% CI 6.91–15.77) \( p < 0.001 \)). In contrast, parallel arm II patients were seven times more effective to reduce the risk of expected CVD development in 10 years than arm I (OR 7.54 (95% CI 3.76–10.32) \( p < 0.001 \)).

Conclusions: The trial concluded that ascorbic acid with metformin is more effective against reducing risks for diabetes related long-term complications (including ACR).

INTRODUCTION

Diabetes mellitus (DM) is one of the most important worldwide health problems with an increasing prevalence. A figure of about 592 million is expected to be raised by 2035. To improve quality of diabetic care, clinical guidelines should be implemented [1]. Considerable resources are committed to addressing important clinical interventions connected with the amelioration of diabetic-induced micro- and macrovascular complications [2]. Under diabetic conditions, ROS are produced mainly through the glycation reaction. Oxidative stress can in turn promote glycation of hemoglobin [3] and impair the ability of \( \beta \)-cells of the pancreas for insulin secretion [4]. Several reports have shown that patients with low concentration of antioxidants are at increased risk of diabetes complications [5, 6]. The beneficial effect of ascorbic
acid consumption in diabetes is controversial. Systematic review of observational studies and meta-analysis of RCTs identified a significant correlation between ascorbic acid as an essential micronutrient and improvements in FBS level in diabetics [7]. The idea that due to impairment of insulin secretion and ascorbate cycle in DM, ascorbic acid is necessary to optimize the insulin secretory function of the islet cells [8]. It has been speculated that decreased circulating ascorbic acid level may contribute to hyperlipidemia in diabetic patients [9]. Vitamin C deficiency, might lead to impaired transport of long-chain fatty acids into the mitochondria and subsequently more triglyceride synthesis in these patients [10]. Observational studies and meta-analysis of RCTs identified a significant correlation between ascorbic acid and improvements in FBS level in diabetics. However, yet large-scale randomized trials are needed to investigate the effect of ascorbic acid supplementation on FBS and HbA1c. It might be appropriate to suggest that diabetic subjects without contraindication of ascorbic acid intake might benefit more from taking ascorbic acid from either natural sources and/or fortified foods, and ascorbic acid supplementation [7]. Observational studies and meta-analysis of RCTs identified a significant correlation between ascorbic acid and improvements in FBS level in diabetics. However, yet large-scale randomized trials are needed to investigate the effect of ascorbic acid supplementation on FBS and HbA1c [7].

Aspirin, one of the most widely used medications worldwide. It has been used as an analgesic, antipyretic, and anti-inflammatory for a long time ago. Recently, Aspirin was found not only to be used as an anti-platelet aggregation and as a chemoprevention for cardiovascular diseases, but also it plays an important role in the reversal of obesity- and diet-induced insulin resistance [11]. As an old drug for new use, offers unique approaches for the treatment of type 2 diabetes because of its insulin-sensitizing and anti-inflammatory properties [12]. Recent studies also indicated that aspirin might be an insulin sensitizing agent and they may be used to reverse hyperglycemia, hyperinsulinemia, and dyslipidemia by sensitizing insulin signaling and improving insulin resistance [13]. Therefore, the objective of this trial was to investigate the efficacy of ascorbic acid and acetylsalicylic acid in type II diabetes mellitus patients using metformin (only) for diabetes management and preventing cardiovascular complications.

Methods

Trial registration
Nederland trial register (NTR)—TC6100 (20th October, 2016) (WHO international clinical trial registry platform). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=6100.

Study design
This trial is a randomized (systemic), single blinded, Multi-center, controlled, and parallel (2 arms) clinical trial. The trial was performed in compliance with the WMA [World Medical Association] Declaration of Helsinki: ethical principles for medical research involving human subjects amended by 59th WMA (Number PHRC/HC/11/13), 2013 Seoul, Korea. Trial was approved by Clinical Research Committee (CRC) 2015, Ministry of Health (MOH), Malaysia. The trial protocol followed the Good Clinical Practice (GCP) guidelines, MOH, Malaysia.

Study population
The study participants consist of patient diagnosed with type 2 diabetes mellitus (T2DM) and attending the outpatient department (OPD) for diabetic treatment. Participants’ eligibility criteria based on: newly diagnosed T2DM (<5 years) with metformin (metfm) only, age ≥18 years without any other systemic and inflammatory disease (e.g., hypertension, arthritis, thyroid disorders, obesity renal impairment, pregnancy, breast feeding, cancer etc.) visiting primary health care centers for follow-up at five different locations in Pulau Pinang, Malaysia. Participants were eligible if they have glucose intolerance from last three-assessments (FBS > 7 mmol/l & Hb1Ac > 7%) and this was proven by patients’ medical history records obtained from the recruitment sites. Participants were excluded if they were using any other prescription drug or regularly using nonsteroidal anti-inflammatory drugs and documented intolerance to vitamin c and/or aspirin.

Trial duration
The clinical trial was a 12-month (1 year) long with five-point (baseline—3 months—6 months—9 months—12 months) assessment (October 2015–August 2016).

Intervention strategy
The study estimated the sample size of 135 per group to detect a reduction in metabolic and cardiovascular markers with p value 0.05 & a power of 80%, and also expected dropout rate of 20%. Thus, investigators aimed to recruit 450 patients. A total of 512 participants were assessed for eligibility, only 456 patients were enrolled for trial. Recruited patients were randomly (systemic) assigned to three groups, 152 patients per arm as follow (allocation ratio 1:1:1):

(a) Control arm (metformin + Placebo) (n = 152). Patients of control arm received usual metformin (Glucophage) with Placebo once daily (blinded).
(b) Parallel arm I (metformin + Ascorbic Acid (ACA) 500 mg) (n = 152)
Recruited patients were given Ascorbic Acid 500 mg (Sundown vitamin c-500) once daily (Blinded) in addition to usual metformin (Glucophage) dose.

(c) Parallel arm II (metformin + Acetylsalicylic Acid (ASA) 100 mg) (n = 152).
Patients received a dose of Acetylsalicylic Acid 100 mg (Apirin® Cardio) once daily in addition to usual metformin (Glucophage) dose.

Note Addition of placebo to control group was aimed to avoid bias in treatment with behavioural effect; if any patient from control arm incidently interact with patients’ of parallel arms (I or II).

Participants of all three groups were advices to maintain usual dietary intake as well as daily activities. Initial screening was performed for physical activity (PA) questionnaire [14]. None of the participant reported a high level of PA, majority of participants with low level and remaining at moderate level. In term of social history—smoking, participants were divided into either “ever smoke (ES)” or “never smoke (NS)”.

Enrollment procedure
Patients may be self-referred or referred through their primary physician. All eligible patients were screened to be included in this study. Eligible patients were also introduced to the study protocol by research coordinator to confirm participation (enrolled from 5 government clinics). Patients who were interested to participate in this study, required to sign a research informed consent form. Patients, who were illiterate, acquire an impartial witness to explain the study protocol before participating. Consolidated standards of reporting trials (CONSORT) flowchart can be seen in Fig. 1.

During the data collection process, all study forms were labelled with a unique study identifier. All collected forms were stored in a locked file cabinet in a locked office. Researcher will check for any missing or outlier values. All the participants monitored for 12 months, and participants provided to each participant’s visit that they were participating on voluntarily basis and thus could decline at any time of study. All the positive efforts were added to minimize any potential bias and also to conduct this study in the most ethical manner possible.

Withdrawal criteria
Following is the withdrawal criteria used to identify dropouts and manage response among participants.

Tools and assessments
Body Mass index (BMI): Seca Stadiometer, as Obesity is in inclusion criteria so allowed limit ≤0 kg/m². Seca non-elastic tape was used to determine waist circumference (WC)

Blood Pressure (BP): Manual sphygomanometer, three readings were taken 2 min apart (mean consider at baseline)

Fasting blood sugar: An enzymatic colorimetric method with glucose oxidase was used, required normal value <5.6 mmol/l

Lipid profile: Total Cholesterol (Total-c), Triglycerides (TG), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) were assessed by using commercial available kits

Framingham risk scale: Was used to assess the 10-year risk for development of cardiovascular disorders. Individual score was calculated as per point system and then took a mean for whole arm. Criteria: low risk ≤ 10%, moderate risk 11–19%, high-risk ≥ 20%

Risk factors for Diabetes related complications: These factors were selected from the national diabetes management guidelines; HbA1c, BP, Albumin-to-Creatinine Ratio (ACR), estimated Glomeruler Filtration Rate (eGFR), lipid profile, smoking, medical follow-ups (regular), retinopathy, ethnicity. Criteria: low risk ≤1 factor, moderate risk 2 factors, high risk ≥3 factors. Individual score was calculated as per point system and then took a mean for whole arm

24/7 emergency call number: all the participants had access to 24/7-helpline number, any adverse effect/event or side effect were directly reported followed by detailed clinical examination for the possible reason.

Note: A trained nurse of the health care centre drew a 7 ml blood sample on each visit, stored in two polyethylene evacuated tubes for quantitative measures (FBS, lipid profile, ACR and eGFR). All the qualitative measures were performed at the respective site of recruitment. Only Glycated Haemoglobin (HbA1c) evaluated every 3rd month, all the other clinical parameters assessed on monthly basis.

All the participants were assured of confidentiality clause in the research protocol. Regular reminders provided to each participant’s visit that they were participating on voluntarily basis and thus could decline at any time of study. All the positive efforts were added to minimize any potential bias and also to conduct this study in the most ethical manner possible.
(a) Discontinue (D/c) patient follow-ups: participant withdrew consent and/or non-cooperative.

(b) Participant developed condition or disease or illness that changed clinical parameters or study environment.

(c) Intolerance/hypersensitive to study supplements: developed condition within 4 h of study supplement administration.

(d) Female participants became pregnant.

(e) Participants were clearly instructed to not take any other OTC drugs without informing the investigator at 24/7-helpline, if investigator somehow identified the use of any medications (OTC or prescribed)/herbal supplements/multivitamin supplements in any participant lead to instant D/c from the trail.

(f) Study supplements were dispensed on monthly basis, so participants were required to keep a
logbook and their entries were monitored. Any patient found nonadherence was removed from the trial.

Note All the participants received a voice reminder daily at dose time to ensure adequate adherence.

Statistical analysis
Data analysis was made using IBM SPSS Statistics, version 22 (Armonk, NY). A probability of $p < 0.05$ was considered statistically significant for all tests. Continuous variables were tested for normality; any non-normal values were categorized or transformed. All variables were analyzed using descriptive analysis. Unadjusted comparisons between study arms were made using t tests for continuous variables or Chi square tests for discrete variables. One-way ANNOVA were used to assess the difference between the groups at the baseline of randomization. Independent t-tests were used to assess the difference between the groups during and end point of the trial. Paired t-tests were used to evaluate the difference within the groups.

Note Intention-to-treat and repeated ANNOVA are not applied in the final analysis as they are primarily used to explore the time and treatment effect however our study objectives are to “compare and estimate the clinical effects of Ascorbic acid with salicylic acid in combination with metformin among diabetes patients”; we are not aimed to compare the time and treatment effect among patients.

Results
Trial participants and intervention
This clinical trial was aimed to determine the effect of vitamin c (ascorbic acid) and aspirin (acetylsalicylic acid) on metabolic markers (FBS, LDL, HDL, Triglycerides etc.) of type 2 Diabetes mellitus (T2DM) in combination with metformin (diabetic medication) only. The effect was compared with control group received placebo in combination with metformin. The trial was design in way to avoid all the possible bias by blinding the study supplements (single blind with placebo, ascorbic acid & acetylsalicylic acid). A 12-month long-term follow-up was managed to evaluate the impact of combinations on risks for development of cardiovascular disorders (Framingham scale) and also on risk factors for development/progression of diabetes related complications. The progression of participants in the trail is shown in Fig. 1. Four hundred and twenty-two patients completed the study, a total of thirty-four patients were discontinue during follow-up because they met one or more of the withdrawal criteria (ten patients from control group, thirteen patients from parallel arm I and eleven patients from parallel arm II) (Fig. 1. Consolidated Standards of Reporting Trials (CONSORT) flowchart).

Equity and balance at baseline
The baseline assessments include: demographic (age, gender, duration of diabetes history, physical activity), anthropometric (BMI, WC), clinical characteristics (HbA1c, FBS, Lipid profile, ACR, eGFR) and clinical markers (Framingham Scale, Risk factors for diabetes related complications) for quantify the long-term diabetes related complications of the participants in all three groups were compared (Table 1). Four hundred fifty-six patients were recruited at the baseline of the trial. To determine the balance in-between the groups, statistical analysis performed among all the patients.

Findings showed no significant difference among compared variables; no difference in terms of age, gender, smoking habit, physical activity or duration of diabetes history. Also, equality in-between the groups were ensured with non-significant difference of BMI & WC comparison for male and female. Similarly, no significant difference was detected when comparing the groups in term of clinical characteristics and clinical markers. Thus, such results indicate balance and equity at baseline between the groups, because the statistical significance didn't reach the level of $p \leq 0.05$.

Glucose tolerance (FBS & HbA1c) pattern in the trial
Within group assessment showed significant difference with FBS from baseline to 12 months of the trial: Parallel arm I (Mean ± SD: 7.65 ± 2.52 to 5.18 ± 1.66, $p < 0.01$) and Parallel arm II (Mean ± SD: 7.71 ± 2.84 to 6.27 ± 2.19, $p < 0.05$) however no significant difference was detected in control arm (Table 2).

Intergroup assessment showed significant difference between control arm and parallel arm I ($p < 0.001$), similar pattern was observed with control arm versus parallel arm II ($p < 0.01$). Comparison between parallel arm I with parallel arm II from baseline to 3 months showed mild significance ($p < 0.05$) however as trial progressed highly significant ($p < 0.01$) difference was observed at 12th month (end of trial) (Fig. 2). Data was transform to estimate the difference between parallel arm I and II, Odd ratios (OR) showed that patients with ascorbic acid (parallel arm I) were three times more likely to reduce FBS than patients with acetylsalicylic acid (parallel arm II) (OR 3.44 (95% CI 1.60–5.68) $p < 0.001$).

Similar pattern was observed with HbA1c, significant reduction was observed within the group with both parallel arm I and II ($p < 0.001$ and $p < 0.001$), Mean reduction of HbA1c was 2.78 (parallel arm I) versus 2.24 (parallel arm II). Findings also suggested that patients
Table 1 Demographic and clinical variables at baseline (randomization) in all three arms (n = 456)

| Variables                                           | Control arm a (n = 152) | Parallel arm b (n = 152) | Parallel arm II c (n = 152) | X²/t | p value |
|-----------------------------------------------------|-------------------------|--------------------------|---------------------------|------|---------|
|                                                     | Mean (SD)/percent       | Mean (SD)/percent        | Mean (SD)/percent         |      |         |
| A. Demographic                                      |                         |                          |                           |      |         |
| Age (years)                                         | 37.93 (7.89)            | 38.12 (8.16)             | 37.49 (6.72)              | 0.08 | 0.87**  |
| Gender                                              |                         |                          |                           | 0.02 | 0.13†   |
| Male                                                | 93 (61.2%)              | 90 (59.2%)               | 95 (62.5%)                |      |         |
| Female                                              | 59 (38.8%)              | 62 (40.8%)               | 57 (37.5%)                |      |         |
| B. Clinical variables                               |                         |                          |                           |      |         |
| Duration of diabetes (yrs)                          | 2.87 (1.22)             | 2.47 (2.48)              | 3.02 (1.97)               | 0.07 | 0.36**  |
| FBS (<5.6 mmol/l)                                   | 8.13 (3.17)             | 7.65 (2.52)              | 7.71 (2.84)               | 0.94 | 0.27**  |
| HbA1c (≤5%)                                         | 9.48 (1.62)             | 8.83 (2.41)              | 9.03 (1.88)               | 0.71 | 0.45**  |
| BMI (kg/m2)                                         | 24.3 (3.45)             | 23.5 (4.22)              | 23.7 (5.13)               | 0.59 | 0.74**  |
| Male                                                | 27.1 (4.05)             | 28.5 (5.10)              | 26.6 (5.70)               | 1.02 | 0.24**  |
| Female                                              | 23.4 (6.03)             | 26.2 (5.96)              | 24.8 (5.79)               | 2.07 | 0.38**  |
| Smoker                                              |                         |                          |                           | 0.26 | 0.16†   |
| Ever smoke (ES)                                     | 15 (9.9%)               | 21 (13.9%)               | 19 (12.5%)                |      |         |
| Never smoke (NS)                                    | 137 (90.1%)             | 143 (94.1%)              | 133 (87.5%)               |      |         |
| BP                                                  |                         |                          |                           | 0.11 | 0.29†   |
| (<130/80 mm Hg)                                     | 12 (7.9%)               | 17 (11.2%)               | 13 (8.6%)                 |      |         |
| (≥130/80 mm Hg)                                     | 140 (92.1%)             | 135 (88.8%)              | 139 (91.4%)               |      |         |
| Waist circumferences (cm)                           | 94 (10.01)              | 93 (10.44)               | 95 (12.44)                | 0.65 | 0.71**  |
| LDL-c (< 2.6 mmol/l)                                | 3.12 (0.98)             | 3.09 (1.12)              | 3.19 (1.19)               | 0.21 | 0.48**  |
| HDL-c (1.0–1.5 mmol/l)                              | 0.98 (1.27)             | 1.01 (0.87)              | 0.95 (1.06)               | 0.31 | 0.62**  |
| Total-c (<5.2 mmol/l)                               | 6.11 (2.48)             | 5.97 (2.69)              | 6.07 (2.71)               | 0.73 | 0.77**  |
| Triglycerides (<1.7 mmol/l)                         | 1.84 (1.02)             | 1.91 (1.12)              | 1.93 (1.09)               | 0.67 | 0.35**  |
| ACR (mg/mmol)*                                      | 3.79 (2.66)             | 3.82 (2.31)              | 3.89 (2.59)               | 0.98 | 0.98*   |
| eGFR (>60 ml/min/1.73 m²)                            | 101.21 (15.37)          | 107.44 (13.84)           | 106.32 (15.91)            | 0.61 | 0.81**  |
| Assessment of risk for diabetes related complications†(≥3 factors) | 3.82 (1.81)             | 3.90 (1.67)              | 4.03 (1.79)               | 0.85 | 0.61**  |
| Framingham risk score‡                               | Mean (SD)               | Mean (SD)                | Mean (SD)                 |      |         |
| Low risk (<10)                                      | 20.34 (3.12)            | 21.98 (4.41)             | 20.18 (4.02)              | 0.71 | 0.32**  |
| Moderate risk (10–19)                               | High                    | High                    | High                      |      |         |
| High risk (≥20)                                     | High                    | High                    | High                      |      |         |
| Physical activity                                    | High                    | –                       | –                         | 0.91 | 0.49†   |
| Moderate                                             | 54 (35.5%)              | 50 (32.9%)               | 57 (37.5%)                |      |         |
| Low                                                  | 98 (64.5%)              | 102 (67.1%)              | 95 (62.5%)                |      |         |

BP: blood pressure, BMI: body mass index, HbA1c: glycated hemoglobin, FBS: fasting blood sugar, LDL-c: low density lipoproteins cholesterol, HDL-c: high density lipoprotein cholesterol, Total-c: total cholesterol, ACR: albumin-to-creatinine ratio, eGFR: estimated glomular filtration rate, IQR: interquartile range

a One way—ANOVA

b Chi square

c Metform with placebo OD (Blinded)

d Metform with acetylsalicylic acid 100 mg OD (blinded), * Males: <2.5 mg/mmol & females: 3.5 mg/mmol

e Risk factors: HbA1c, BP, ACR, eGFR, Lipid profile, smoking, medication reviews (regular checkups)

* Framingham Risk score: Canadian cholesterol guidelines to predict 10-years risk of developing cardiovascular disease—individualize score was calculated first then check for mean ± SD
with metformin and ascorbic acid (parallel arm I) were two times more likely to reduce HbA1c than metformin alone (control arm) in a year (OR 2.31 (95% CI 1.87–4.42) p < 0.001).

Effect of trial on anthropometric values
Neither ascorbic acid nor acetylsalicylic acid showed any significant change (reduction or increase) to anthropometric values both within the group and intergroup (compare to control) (Table 2).

Effect of trial supplements on Lipid profile
Within group assessment showed that mean reduction of LDL-c was significantly (p < 0.001) reduced to (2.16) from (3.19) among patients receiving acetylsalicylic acid (parallel arm II), mild significance (p < 0.05) was also associated with parallel arm I. In contrast participants receiving metformin (control arm) alone showed significant (p < 0.05) increase in value to (3.56) from (3.12).

Intergroup assessment presented significant difference between parallel arm I & II compared to control arm (p < 0.03 and p < 0.001). Similar patterns were observed with other lipid parameters (Table 2).

Participants of parallel arm II were two times more likely to reduce LDL-c as compared to participants of parallel arm I in a year (OR 2.06 (95% CI 1.21–4.78) p < 0.001).

HDL-c values were increased at the same level among the participants of both parallel arms (OR 1.04 (95% CI 0.16–1.77) p < 0.91). Similar pattern was observed with TG (triglycerides) in comparison between parallel arm I and parallel arm II. However participants with acetylsalicylic acid (parallel arm II) were four times more likely to reduce Total-c (total cholesterol) as compared to patients received metformin alone (control arm) in a year (OR 4.35 (95% CI 2.19–7.46) p < 0.001).

Changes in ACR & eGFR estimates
Albumin-to-creatinine ratio (ACR) value was significantly (p < 0.001) reduced within ascorbic arm during the trial, both control arm and acetylsalicylic acid arm didn't show any difference as compared to baseline. It was estimated that participants with ascorbic supplement in combination with metformin (parallel arm I) is five times more likely to reduce the mean ACR value than metformin alone (control arm) in a year (OR 5.16 (95% CI 2.81–7.93) p < 0.001).

eGFR; Participants of ascorbic acid and acetylsalicylic acid were exhibited no significant difference from baseline to endpoint within a group assessment. Also intergroup assessment showed no difference among all three arms. However, patients with metformin alone (control arm) showed mild significant reduction in eGFR (p < 0.05) from baseline to endpoint of trial suggesting possible deterioration of renal function due to glucose intolerance overtime (Table 2).

Risk factors for developing Diabetes related long-term complications
The interventional arms (I & II) were showed significant (p < 0.001) reduction of risk factors contributing to long-term diabetes related complications from baseline to endpoint (Table 2). Intergroup assessment between parallel arm I and arm II suggested that participants with arm I were ten times more likely to reduced risk factors contributing to long-term diabetes complications than participants of arm II in a year (OR 10.38 (95% CI 6.91–15.77) p < 0.001) (Fig. 3).

Change of Framingham risk score respective to trial supplement
The study supplements showed significant association with the reduction of Framingham score in the trial compared with baseline; arm I (p < 0.001, moderate): arm II (p < 0.001, Low), however control arm presented an increase in mean score sustaining ‘high risk’ (Table 2). Comparison between arm I & arm II to estimate the impact of effect showed that patients with acetylsalicylic arm II were seven times more effective to reduce the risk of expected CVD development in 10 years than ascorbic arm I (OR 7.54 (95% CI 3.76–10.32) p < 0.001) (Fig. 3).

Adverse drug reactions/events reported via 24/7-helpline
A total of 133 diabetes related complications/complaints were reported in a year, among them control arm (89, 66.9%), parallel arm I (23, 17.3%) and rest 21 (15.8%) from parallel arm II. Followings were the distribution pattern with the study arms; Missed dose: 25 (18.8%) with Control arm only.

Hypoglycemic episodes: 45 (33.8%) Control arm, 3 (2.3%) Parallel arm I, and 5 (3.7%) with Parallel arm II.

Hyperglycemic episodes: 45 (33.8%) Control arm, 3 (2.3%) Parallel arm I, and 5 (3.7%) with Parallel arm II.

Wrong timing of medication intake: 11 (8.2%) Control arm, 5 (3.7%) Parallel arm I, and 4 (3.0% Parallel arm II).

Above finding clearly suggested increased number of diabetes related medication nonadherence and intolerance complaints with control arm as compared with parallel arm I and II. Results reflected the reduced non-adherence and intolerance episodes with both ascorbic and acetylsalicylic arm in a year.

Discussion
Generally scientific literature suggested decrease antioxidative system of the body with diabetes mellitus over period of time, thus increased the oxidative load [16].
Table 2 Change in clinical variables after intervention among three arms (n = 422)

| Variables          | Control Arm (n = 142) | Parallel arm I (n = 139) | Parallel arm II (n = 141) |
|--------------------|-----------------------|--------------------------|---------------------------|
|                    | Mean ± SD             | Baseline                 | 12 month                  | Mean ± SD             | Baseline                 | 12 month                  | p value* (paired samples t test)   | p value* (paired samples t test)   |
| BP (≤130/80 mm Hg) |                       |                          |                           |                        |                          |                           |                               |                               |
| >130/80 mm Hg      | 12–7.9%               | 25–16.5%                 | 17–11.2%                  | 88–57.9%               | 13–8.6%                  | 102–67.1%                 | 0.001                         | 0.01                           |
| LDL-c (<2.6 mmol/l)| 3.12 ± 0.98           | 3.56 ± 1.17*             | 3.90 ± 1.12               | 2.47 ± 2.11            | 3.19 ± 1.19              | 2.16 ± 0.78               | 0.03                          | 0.001                          |
| HDL-c (1.0–1.5 mmol/l)| 0.98 ± 1.27          | 0.76 ± 1.02*             | 1.01 ± 0.87               | 1.37 ± 1.03            | 0.95 ± 1.06              | 1.39 ± 1.11               | 0.01                          | 0.001                          |
| Total-c (<5.2 mmol/l)| 6.11 ± 2.48           | 6.44 ± 3.65**            | 5.97 ± 2.69               | 5.07 ± 1.49            | 6.07 ± 2.71              | 4.8 ± 1.89**              | 0.04                          | 0.001                          |
| Triglycerides (<1.7 mmol/l)| 1.84 ± 1.02        | 2.11 ± 1.78*             | 1.91 ± 1.12               | 1.28 ± 0.67            | 1.93 ± 1.09              | 1.16 ± 0.73**             | 0.02                          | 0.001                          |
| ACR (mg/mmol)      | 3.79 ± 2.66           | 3.81 ± 2.03              | 3.81 ± 2.31               | 2.32 ± 1.98            | 3.80 ± 2.59              | 3.22 ± 2.06               | 0.001                         | 0.45                           |
| eGFR (>60 ml/min/1.73 m²)| 101.21 ± 15.37   | 97.89 ± 18.20*           | 107.44 ± 13.84            | 106.71 ± 13.01         | 106.32 ± 15.91           | 107.86 ± 14.37            | 0.21                          | 0.37                           |
| Assessment of risk for diabetes related complications (≥3 factors) | 3.82 (1.81) | 4.01* (2.03) | 3.90 (1.67) | 0.82** (1.01) | 4.03 (1.79) | 1.67** (0.88) | 0.001 | 0.01 |

| Framingham risk score | 0.001 |
| Low risk (<10) | High risk | High risk | High risk | High risk | High risk | Low risk |
| Moderate risk (10–19) | 20.34 ± 3.12 | 21.42 ± 2.65 | 21.98 ± 4.41 | 11.69 ± 2.99** | 20.18 ± 4.02 | 7.23 ± 1.22** | 0.01 |
| High risk (≥20) | Physical activity | 0.04‡ | 0.01‡ |
| High | – | – | – | 15–9.9% | – | 19–12.5% |
| Moderate | 54–35.5% | 69–45.4% | 50–32.9% | 71–46.7% | 57–37.5% | 69–45.4% |
| Low | 98–64.5% | 83–54.6% | 102–67.1% | 66–43.4% | 95–62.5% | 64–42.1% |

BP: blood pressure, BMI: body mass index, HbA1c: glycated hemoglobin, FBS: fasting blood sugar, LDL-c: low density lipoproteins cholesterol, HDL-c: high density lipoprotein cholesterol, Total-c: total cholesterol, ACR: albumin-to-creatinine ratio, eGFR: estimated glomerular filtration rate, IQR: interquartile range, Mod: moderate

* p < 0.05

** p < 0.01 (two-tailed) (paired samples t test)

a Independent-samples t test

‡ Chi square

a Metfm with Placebo OD (Blinded)

b Metfm with Ascorbic Acid 500 mg OD (Blinded)

c Metfm with Acetylsalicylic Acid 100 mg OD (Blinded)

d Risk factors: HbA1c, BP, ACR, eGFR, Lipid profile, smoking, medication reviews (regular checkups)

* Framingham Risk score criteria: Canadian cholesterol guidelines to predict 10-years risk of developing cardiovascular disease—individualize score was calculated first then check for mean ± SD
Several observational epidemiological studies reported the increase risks of diabetes related complications with low level of antioxidants [6, 17]. Some experimental researches also supported the oxidative stress role in pathogenesis of diabetes and related complications [18, 19].

This influenced the scientific community from all across the globe to determine the correlational pattern between diabetes management and antioxidants. So, numerous human and animal studies were performed over last two decades, to estimate the positive effects of antioxidant therapy on oxidative stress status [via Reactive Oxygen species (ROS)], relative influence on b-cell mass and insulin secretion [19–21]. However, antioxidants beneficial role on insulin resistance/sensitivity pattern is far from exclusive [22, 23]. Also Oral Ascorbic acid supplementation ameliorates skeletal muscle oxidative stress during hyperinsulinemia and improves insulin-mediated glucose disposal in people with type 2 diabetes [24].

Hydrophilicity and concentration dependent action of Vitamin C (ascorbic acid) could have both pro- and antioxidative functions [25]. It is believed that ascorbic acid optimizes the islets’ insulin secretion, to facilitate impaired insulin secretion and ascorbate cycle in diabetes mellitus [8].

There are several in vitro and in vivo studies to determine the influence of antioxidants in diabetes management. Chen and colleges [26] conducted a RCT with T2DM patients including 800 mg ascorbic acid interventional arm and compared to Placebo over a period of 4 weeks, findings showed nonsignificant effects to glucose tolerance parameters (FBS etc.). In contrast, Evans and colleagues [27] conducted similar RCT with T2DM patients but increase the ascorbic acid dose to 1000 mg and compared to Placebo over a period of 6 weeks, results showed significant decrease in TG, increase in HDL-c, decrease in SBP&DBP and also FBS levels with ascorbic acid group compared with placebo. Likewise, Paolisso and team [28] also conducted a RCT in T2DM patients including ascorbic acid 1000 mg versus Placebo over 16 weeks of follow-up, findings suggested significant decrease in TG, LDL-c, HbA1c, FBS also whole body glucose disposal with ascorbic acid group compared with placebo. These trials limited with the standardization of hyperglycemic agents used by trial participants and also the short duration and high dose of ascorbic acid. The high doses of ascorbic acid have adverse effects such as oxidative damage to DNA and decrease NO bioactivity [29]. As discussed early ascorbic acid exhibits concentration-dependent action to antioxidative functions, and significant reduction in diabetes assessment parameters (FBS, HbA1c etc.) are not truly the effects of ascorbic acid alone; other hyperglycemic agents in combination to antioxidants also influence the value of assessment parameters [30, 31]. Thus control the use of hyperglycemic medications in the trial participants would provide a true picture of ascorbic acid effect in diabetes.
This trial showed significant reduction in FBS, HbA1c, Diabetes related long-term complications, LDL-c, TG, Total-c, also Framingham score for 10-years risk of developing CVD with ascorbic acid group compared to control group. This trial benefitted with the 48 weeks (long term follow up) as compared with 4–12 weeks trails before; also controlled the impact of hyperglycemic agents by standardizing metformin use only by all the trial participants (interventional arms and control arm). All the previous literature [17, 26] lacked to provide the combination effect of metformin with ascorbic acid. Similarly, other trials only discussed the effect of ascorbic acid on the management of current diabetes assessment parameters, none correlates the effect/impact of ascorbic acid use on long-term diabetes related complications & development of CVDs over time. Also among type 2 diabetic patients, low levels of serum vitamin C were closely associated with concomitant renal dysfunction and low-grade inflammation [32].

However recent meta-analysis didn’t support the beneficial effect of antioxidants on homoeostatic model assessment index (HOMA) and also identified the lack of evidence on long-term use of antioxidants in diabetes [33, 34]. Thus, this trial answered the limitations of meta-analysis report by comparing low dose antioxidants (500 mg) with metformin for long duration of time (48 weeks) against metformin with placebo. This trial also reported that antioxidants combination with metformin (only) improved the glucose tolerance and reduced disease progression, these findings consistent with recent in vitro studies [33–35] and ADA recommendations [36].

Recent interest on the theory of chronic low-grade inflammation contributed to pathogenesis of insulin resistance and T2DM provided credible hypothesis to establish the link, thus targeting the inflammatory pathway might enhance the pharmacological response for the treatment of T2DM [30, 37–39]. Safety profile of salicylates, provided wide room for clinical studies to investigate the response in patient with T2DM and also obese non-diabetic individuals [40–45]. Cardiovascular events are the chronic complications of T2DM and aspirin is widely used to reduce such events. Therefore, this trial further investigates the efficacy of aspirin on T2DM and its complications. Furthermore, since asprins are inexpensive, using salicylates for treatment of T2DM would have potential health-economic benefit worldwide [33, 34]. Derosa et al, also reported that the use of ASA in primary prevention could be useful in patients with type 2 diabetes mellitus and hypertension [46].

Several trials in the last decade were conducted to determine the effect of aspirin in diabetes pathogenesis [47–53]. A recent meta-analysis conducted by Fang and colleagues [54] concluded that the anti-diabetic effect of salicylates is in a dose-dependent manner. High doses of salicylates may have beneficial effects on reducing FPG, HbA1c level and increasing fasting insulin concentration, and may also have some positive effects on lipidemia and inflammation-associated parameters for patients with T2DM, without severe adverse effects. It is also reported in the literature that Biomarkers of inflammation and endothelial dysfunction were positively associated with incident T2D [55, 56]. All the previous trials were limited to:

(a) None of the trials have determined the combine drug effects (metformin with aspirin).
(b) Comorbidities were not controlled among all the trial participants (diverse data).
(c) Neither of the trials has compared the inflammatory effect of aspirin with antioxidant effect of ascorbic acid (control variable: diabetic medication, metformin) nor determines the better treatment option.
(d) Also, effect of aspirin on long-term diabetes related complications, lipid profile, and Framingham scale for risks of CVD development never evaluated before.

This trial manage to standardize the use of metformin (alone) for diabetes in all the participants, also all the patients with any systemic or inflammatory diseases (including pregnancy) were excluded in the early recruitment phase to avoid impact of disease on relative assessment variables. Previous literature suggested that high dose >1000 mg/day significantly reduced the FBS [47], but this trial reported significant reduction of FBS within 3 months with aspirin 100 mg/day (parallel arm II) compared with control (metformin only). Thus preventing adverse drug reactions with high doses, e.g., gastrointestinal discomforts, extremity edema, hemorrhage risks etc. Low doses of aspirin are widely used to prevent cardiovascular events in high-risk patients [55, 56]. The results of our trial showed that low doses of aspirin had significantly positive effects on glucose metabolism, lipidemia and reduced CVD development risks in patients with T2DM. Aspirin improves the glucose metabolism for patients with T2DM through inhibiting IKKβ/NF-κB axis. However, so far no trial have used high doses of aspirin to reduce cardiovascular events, this is the first trial that determine and estimate the reduction of cardiovascular event by using Framingham scale.

Most importantly scientific literature is diverse with the antioxidants versus anti-inflammatory agents use in diabetes; several trials have shown beneficial outcomes with both. But none of them have compared the ascorbic acid versus aspirin in RCT to determine benefits with glucose metabolism, lipid profile and reduction in both CVD risks and risks for long-term diabetes related
complications (Additional file 1). Type 2 diabetic patients who were started on metformin monotherapy showed improvement in many of the clinical parameters and a reduction in all-cause mortality and CVD events than lifestyle modifications alone [57, 58]. If there is no contraindication and if tolerated, diabetic patients should be prescribed with metformin early in the course of the diabetic management to minimize their risk of having the cardiovascular events and mortality in the long run [58–62]. Lastly, differences of HDL-C levels in response to metformin by race/ethnicity, and that racial and ethnic identity is a factor to consider when interpreting the effects of metformin treatment [63].

Conclusions
The strength of our study lies in the comparison between interventional arms and control group at the end point of the study without violating any patients’ characteristics, so equality was assumed in all aspects. To the best of our knowledge, no previous studies have evaluated comparison of clinical efficacy of ascorbic acid and aspirin in combination with metformin. Our findings indicate significant improvement in glucose metabolism and lipid-profile variables with both interventional arms (ascorbic acid vs aspirin). The trial concluded that ascorbic acid with metformin is more effective against reducing risks for diabetes related long-term complications (including ACR), however if the treatment goal is to reduce cardiovascular events or risks for CVD development then aspirin with metformin is benefitted over ascorbic acid.

Further RCT studies with different diabetic medications are needed to explore the efficacy of antioxidants in diabetes with comorbidities.

Additional file

Additional file 1. Improving clinical care of diabetes mellitus; randomized clinical trial.

Authors’ contributions
SWG is the principle investigator, design and conduct the trial, participated in content validation and analysis and also drafted the manuscript. SASS is co-investigator and participated in data collection and analysis. MIMA conducted the content analysis and data validation. MRB provided literature support, linguistic help and copy editing to manuscript draft. All authors read and approved the final manuscript.

Author details
1 College of Pharmacy, Taibah University, Medina, Al-Madinah Munawarah, Saudi Arabia. 2 Pharmacotherapy Research Group, Islamabad, Pakistan. 3 Pharmacotherapy Research Group, Kuala Lumpur, Malaysia. 4 School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM), George Town, Malaysia. 5 College of Pharmacy, University of Philippines, Quezon, Philippines. 6 Dubai College of Pharmacy, Dubai, UAE.

Acknowledgements
We would like to acknowledge the efforts of nurses and other relevant staffs for collecting data, conducting this trial, organizing patients’ meetings and effectively record the trial data. Also want to express our gratitude to our trial participants for honesty and co-operation during the trial.

Competing interests
The authors declare that they do not have anything to disclose regarding funding or conflicts of interest with respect to this work.

Availability of data and materials
All the data is available with Dr. Syed Wasif Gillani, reasonable request will be responded with supplementary raw-data.

Consent for publication
Not application with respect to patients, all the authors agreed to submission.

Ethics approval and consent to participate
Approved from Ministry of health, Malaysia. Patients who were interested to participate in this study, required to sign a research informed consent form. Patients, who were illiterate, acquire an impartial witness to explain the study protocol before participation.

Funding
Self-sponsored no actual or potential conflict of interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 June 2017 Accepted: 31 July 2017
Published online: 14 August 2017

References
1. Executive summary IDF Diabetes Atlas 6th Edition. International Diabetes Federation, 2013. www.idf.org/sites/default/files/EN_6E_Atlas_Exec_Sum_1.pdf. Last updated 2014. Accessed 3 Nov 2016.
2. Lucioni C, Garancini MP, Massi Benedetti M, Mazzi M, Serra G. per conto dell’Advisory Board italiano dello studio Code-2: Il costosociale del diabete di tipo 2 in Italia: lo studio Code-2. Farmacoencom Ital Res Artic. 2000;1(2):1–21.
3. Madian AG, Myracle AD, Diaz-Maldonado N, et al. Differential carbonylation of proteins as a function of in vivo oxidative stress. J Proteome Res. 2011;10:3959–72.
4. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic beta islet beta cells in diabetes. J Biol Chem. 2004;279:42351–4.
5. Gey K, Puska P, Jordan P, Moser U. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutrit. 1991;53:326S–345.
6. Gey K, Moser U, Jordan P, et al. Increased risk of cardiovascular disease at suboptimal plasma concentration of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am J Clin Nutr. 1993;57:7875–975.
7. Tabatabaei-Malazy O, Nikfar S, Larjani B, Abdollahi M. Influence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized controlled trials: a systematic review with meta-analysis. J Pharm Pharm Sci. 2014;17(4):S54–82.
8. Steffen RJ, Wu L, Powers AC, May JM. Ascorbic acid recycling by cultured beta cells: effects of increased glucose metabolism. Free Radic Biol Med. 2004;37:1612–21.
9. Wilk JE, Bye T. Does diabetes mellitus increase the requirement for vitamin C? Nutr Rev. 1996;54:193–202.
10. Dai S, McNeil JH. Ascorbic acid supplementation prevents hyperlipidemia and improves myocardial performance in streptozocin-diabetic rats. Diabetes Res Clin Pract. 1995;27:11–8.
11. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore L, Lee J, Yuan M, Li ZW, Karim M, Perret P, Shoelson SE, Shulman GI. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437–46.

12. Sun Xiaodong, Han Fang, Yi Junling, Han Lina, Wang Ben. Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats. J Korean Med Sci. 2011;26:765–70.

13. Uan M, Konstantopolous N, Lee J, Hansen L, Li ZW, Karim M, Shoelson SE. Reversal of obesity—and diet-induced insulin resistance with salicylates or targeted disruption of IKK-B. Science. 2001;293:1673–7.

14. Block G, Jensen C, Dietrich M, Norkus E, Hudes M, Packer L. Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. J Am Coll Nutr. 2004;23(2):141–7.

15. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Circulation prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47. doi:10.1161/01.ict.98.18.1837.

16. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants in prophyphaxis and therapy: a pharmaceutical perspective. J Control Release. 2006;113:199–207.

17. Gey K, Puska P, Harris JK, Jordan P, Moser U. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr. 1991;53:3265–345.

18. Johansen JS, Harris AR, Krych D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol. 2006;5(1):1--11.

19. Rahimi R, Nikfar S, Larjani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365–73.

20. Abdel-Wahab YH, O’Harte FP, Mooney MH, Barnett CR, Flatt PR. Vitamin C supplementation decreases insulin glycation and improves glucose homeostasis in obese hyperglycemic (ob/ob) mice. Metabolism. 2002;51:514–7.

21. Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic-cells against glucose toxicity. Diabetes. 1999;48:2398–406.

22. McSorley PT, Bell PM, Young JS, Atkinson AB, Sheridan B, Fee JP, et al. Endothelial function, insulin action and cardiovascular risk factors in young healthy adult offspring of parents with type 2 diabetes: effect of vitamin E in a randomized double-blind, controlled clinical trial. Diabet Med. 2005;22:703–10.

23. Manning PJ, Sutherland WH, Walker RJ, Williams SM, De Jong SA, Ryalls AR, et al. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabetes Care. 2004;27:2166–71.

24. Mason SA, Dell’a Gatta PA, Snow RJ, Russell AP, Wadley GD. Ascorbic acid supplementation improves skeletal muscle oxidative stress and insulin sensitivity in people with type 2 diabetes: findings of a randomized controlled study. Free Radic Biol Med. 2016;93:227–38.

25. Mandj J, Szarka A, Banhegyi G. Vitamin C: update on physiology and paradoxes. Acta Biochim Biophys Acad Sci Hung. 2002;35:263–6.

26. Chen H, Kame R, Hall G, Campia U, Panza JA, Cannon RO 3rd, et al. The effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes. A randomized, double-blind, placebo-controlled study. J Am Coll Nutr. 2000;19(4):349–56.

27. Fearnley GR, Vincent CT, Chakrabarti R. Reduction of blood fibrinolytic activity in diabetes mellitus by insulin. Lancet. 1959;2(7111):1067.

28. Ogston D, McAndrew GM. Fibrinolysis in obesity. Lancet. 1964;2(7173):1205–7.

29. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.

30. Goldfine AB, Silver R, Aldaher W, et al. Use of salaslate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008;1(1):36–43.

31. Goldfine AB, Fonseca V, Jakobsen KA, et al. The effects of salaslate on glycemic control in patients with type 2 diabetes. Ann Intern Med. 2010;152(6):346–57.

32. Fleischman A, Bernier R, Shoelson SE. Salsalate improves glycaemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289–94.

33. Koska J, Ortega E, Bunt JC, et al. The effect of salaslate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomized double-blind placebo-controlled study. Diabetologia. 2008;52(3):385–93.

34. Pierce GL, Lesniakiewicz LA, Lawson BR, et al. Nuclear factor-κB activation contributes to vascular endothelial dysfunction via oxidative stress in over-weight/obese middle-aged and older humans. Circulation. 2009;119(9):1284–92.

35. Ford RJ, Fullerton MD, Pinkslosky SL, Day EA, Scott JW, Oakhill JS, Bujak SM, Blake CR, Hurley SM, et al. Lack of interference of aspirin with arterial fibrinolysis. Am J Cardiol. 2003;91(1):29–30.

36. Camargo EG, Pedrini RO, Gross JL, et al. Aspirin prevents ischemic injury in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. J Clin Invest. 2008;119(2):120–2.

37. Ford RJ, Fullerton MD, Pinkslosky SL, Day EA, Scott JW, Oakhill JS, Bujak SM, Blake CR, Hurley SM, et al. Lack of interference of aspirin with arterial fibrinolysis. Am J Cardiol. 2003;91(1):29–30.

38. Ford RJ, Fullerton MD, Pinkslosky SL, Day EA, Scott JW, Oakhill JS, Bujak SM, Blake CR, Hurley SM, et al. Lack of interference of aspirin with arterial fibrinolysis. Am J Cardiol. 2003;91(1):29–30.

39. Ford RJ, Fullerton MD, Pinkslosky SL, Day EA, Scott JW, Oakhill JS, Bujak SM, Blake CR, Hurley SM, et al. Lack of interference of aspirin with arterial fibrinolysis. Am J Cardiol. 2003;91(1):29–30.

40. Ford RJ, Fullerton MD, Pinkslosky SL, Day EA, Scott JW, Oakhill JS, Bujak SM, Blake CR, Hurley SM, et al. Lack of interference of aspirin with arterial fibrinolysis. Am J Cardiol. 2003;91(1):29–30.
54. Fang FANG, Yu LU, De-lin MA, Ting-ting DU, Shi-ying SHAO, Xue-feng YU. A meta-analysis of salicylates for type 2 diabetes mellitus. J Huazhong Univ Sci Technol. 2013;33(1):1–14. doi:10.1007/s11596-013-1063-5.

55. Odegaard AO, Jacobs DR Jr, Sanchez OA, Goff DC Jr, Reiner AP, Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 2016;24(15):51.

56. Fetterman JL, Hollbrook M, Westbrook DG, Brown JA, Feeley KP, Bretón-Romero R, Linder EA, Berk BD, Weisbrod RM, Widlansky ME, Gokce N, Ballinger SW, Hamburg NM. Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2016;31(15):53.

57. Christie-David DJ, Gunton JE. Vitamin C deficiency and diabetes—easily missed? Diabet Med. 2017. doi:10.1111/dme.13287.

58. Fung CS, Wan EY, Wong CK, Jiao F, Chan AK. Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients. Cardiovasc Diabetol. 2015;14(14):137.

59. Tu H, Li H, Wang Y, Niyati M, Wang Y, Leshin J, Levine M. Low red blood cell vitamin c concentrations induce red blood cell fragility: a link to diabetes via glucose, glucose transporters, and dehydroascorbic acid. EBioMedicine. 2015;2(11):1735–50.

60. Afkhami-Ardekani Shojaoddiny-Ardekani A. Effect of vitamin C on blood glucose, serum lipids & serum insulin in type 2 diabetes patients. Indian J Med Res. 2007;126:471–4.

61. Yamagishi S, Fukami K, Matsu T. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4- incretin system in diabetic vascular complications. Cardiovasc Diabetol. 2015;13(14):2.

62. Dakhale GN, Chaudhari HV, Shravastava M. Supplementation of vitamin C reduces blood glucose and improves glycosylated hemoglobin in type 2 diabetes mellitus: a randomized, double-blind study. Adv Pharmacol Sci. 2011;2011:5. doi:10.1155/2011/195271.

63. Zhang C, Gao F, Luo H, Zhang CT, Zhang R. Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity. Cardiovasc Diabetol. 2015;12(14):79.